Acitretin CAS NO.55079-83-9

4. Appearance:yellow crystalline powder

5. Solubility: practically insoluble in water,  sparingly soluble in tetrahydrofuran, slightly soluble in acetone and in alcohol, very  slightly soluble in cyclohexane. It is sensitive to air, heat and light, especially in  solution.

6. general info: Acitretin is a second generation retinoid. Acitretin is a metabolite of etretinate, which was used prior to the introduction of acitretin. Etretinate was discontinued because it had a narrow therapeutic index as well as a long elimination half-life (t1/2=120 days), making dosing difficult. In contrast, acitretin's half-life is approximately 2 days. Because acitretin can be reverse metabolised into etretinate which has a long half life, women must avoid becoming pregnant for at least 2 years after discontinuing acitretin. Therefore, etretinate is generally not recommended for women of child bearing age with a risk of becoming pregnant. Acitretin is the least toxic systemic treatment for psoriasis. It is an oral retinoid of choice used in the treatment of severe resistant psoriasis. It binds to nuclear receptors that regulate gene transcription. They induce keratinocyte differentiation and reduce epidermal hyperplasia. Acitretin is readily absorbed and widely distributed after oral administration. A therapeutic effect occurs after 2 to 4 weeks or longer. If a patient has received the medication, he/she is advised against giving blood for at least 3 years due to the risk of birth defects.

Application for Acitretin:

1.  Acitretinis widely applied in pharmaceutical field, mainly used for the cure of

dermatonosus like acne, ichthyosis and psoriasis abnormal, etc..

2.  For skin keratinocytes-resistant drugs and cell-induced differentation drug.